Risk stratification in cardiac amyloidosis: Novel approaches

Transplantation

Volumn 80, Issue SUPPL. 1, 2005, Pages

  Kristen, Arnt V ^a   Meyer, F Joachim ^a   Perz, Jolanta B ^a   Schonland, Stefan O ^a   Hundemer, Michael ^a   Hegenbart, Ute ^a   Singer, Reinhard ^a   Schnabel, Philipp A ^a   Sack, Falk Udo ^a   Goldschmidt, Hartmut ^a   Katus, Hugo A ^a   Dengler, Thomas J ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Amyloidosis; Diastolic heart failure; Heart transplantation; Risk stratification

Indexed keywords

AMYLOID PROTEIN; BRAIN NATRIURETIC PEPTIDE; IMMUNOGLOBULIN LIGHT CHAIN; TROPONIN;

CONFERENCE PAPER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; FAMILIAL AMYLOIDOSIS; HEART AMYLOIDOSIS; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE SEPTUM; HOLTER MONITORING; HUMAN; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TILT TABLE TEST;

AMYLOIDOSIS; AMYLOIDOSIS, FAMILIAL; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; HEART TRANSPLANTATION; HUMANS; RISK ASSESSMENT;

EID: 27644525104     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000187111.00076.1a     Document Type: Conference Paper

References (36)

1. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68: 220.
2. Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997; 80: 486.
3. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985; 6: 737.
4. Dubrey SW, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997; 78: 74.
5. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85.
6. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350.
7. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77: 64.
8. Altland K, Winter P, Saraiva MJ, Suhr O. Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Neurogenetics 2004; 5: 61.
9. Altland K. Eine Diät für Familiäre Amyloidose vom Transthyretintyp: Überlegungen zur Verzögerung von Erkrankungsbeginn und Krankheitsverlauf. Available at http://www.med.uni-giessen.de/genetik/ FAP_nahrung.html. Accessed September 1, 2004.
10. Ando Y. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Amyloid 2003; 10: 55.
11. Koyama J, Ray Sequin PA, Falk RH. Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation 2002; 106: 556.
12. Palladini G, Malamani G, Co F, et al. Holter monitoring in AL amyloidosis: prognostic implications. PACE 2001; 24: 1228.
13. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440.
14. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787.
15. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274.
16. Meyer FJ, Borst MM, Zugck C, et al. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 2001; 103: 2153.
17. Squire IB, O'Brien RJ, Demme B, et al. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci 1979 2004; 107: 309.
18. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction; An ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44: 335.
19. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014.
20. Rottbauer W, Greten T, Muller Bardorff M, et al. Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage. Eur Heart J 1996; 17: 3.
21. Hamm CW, Katus HA. New biochemical markers for myocardial cell injury. Curr Opin Cardiol 1995; 10: 355.
22. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med 1998; 91: 141.
23. Oki T, Tanaka H, Yamada H, et al. Diagnosis of cardiac amyloidosis based on the myocardial velocity profile in the hypertrophied left ventricular wall. Am J Cardiol 2004; 93: 864.
24. Sallach JA, Klein AL. Tissue Doppler imaging in the evaluation of patients with cardiac amyloidosis. Curr Opin Cardiol 2004; 19: 464.
25. Trikas A, Rallidis L, Hawkins P, et al. Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis. Am J Cardiol 1999; 84: 1049.
26. Rahman JE, Helou EF, Gelzer Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004; 43: 410.
27. Puille M, Altland K, Linke RP, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002; 29: 376.
28. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681.
29. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881.
30. Razonable RR, Patel R, Wilhelm MP, et al. Fatal disseminated aspergillosis following sequential heart and stem cell transplantation for systemic amyloidosis. Am J Transplant 2001; 1: 93.
31. Mohty M, Albat B, Fegueux N, Rossi JF. Autologous peripheral blood stem cell transplantation following heart transplantation for primary systemic amyloidosis. Leuk Lymph 2001; 41: 221.
32. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: The United Kingdom experience. J Heart Lung Transplant 2004; 23: 1142.
33. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751.
34. Meyer FJ, Zugck C, Haass M, et al. Inefficient ventilation and reduced respiratory muscle capacity in congestive heart failure. Basic Res Cardiol 2000; 95: 333.
35. Lavietes MH, Gerula CM, Fless KG, et al. Inspiratory muscle weakness in diastolic dysfunction. Chest 2004; 126: 838.
36. Falk RH, Monahan KM, Smith TW. Failure of the implantable defibrillator to prevent sudden death in cardiac amyloidosis. Circulation 2000; 102 (suppl II): 396.